Literature DB >> 22126150

Epigenetics of kidney cancer and bladder cancer.

Amanda M Hoffman1, Paul Cairns.   

Abstract

This article focuses on the epigenetic alterations of aberrant promoter hypermethylation of genes, and histone modifications or RNA interference in cancer cells. Current knowledge of the hypermethylation of allele(s) in classical tumor suppressor genes in inherited and sporadic cancer, candidate tumor suppressor and other cancer genes is summarized gene by gene. Global and array-based studies of tumor cell hypermethylation are discussed. The importance of standardization of scoring of the methylation status of a gene is highlighted. The histone marks associated with hypermethylated genes, and the miRNAs with dysregulated expression, in kidney or bladder tumor cells are also discussed. Kidney cancer has the highest mortality rate of the genito-urinary cancers. There are management issues associated with the high recurrence rate of superficial bladder cancer, while muscle-invasive bladder cancer has a poor prognosis. These clinical problems are the basis for the translational application of gene hypermethylation in the diagnosis and prognosis of kidney and bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22126150      PMCID: PMC3314381          DOI: 10.2217/epi.10.64

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  142 in total

1.  Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin.

Authors:  Donghao Shang; Yuting Liu; Yoshiyuki Matsui; Noriyuki Ito; Hiroyuki Nishiyama; Toshiyuki Kamoto; Osamu Ogawa
Journal:  Urology       Date:  2008-06       Impact factor: 2.649

2.  RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking.

Authors:  Erika M Wolff; Gangning Liang; Connie C Cortez; Yvonne C Tsai; J Esteban Castelao; Victoria K Cortessis; Denice D Tsao-Wei; Susan Groshen; Peter A Jones
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c.

Authors:  C Nakada; K Matsuura; Y Tsukamoto; M Tanigawa; T Yoshimoto; T Narimatsu; L T Nguyen; N Hijiya; T Uchida; F Sato; H Mimata; M Seto; M Moriyama
Journal:  J Pathol       Date:  2008-12       Impact factor: 7.996

4.  Identification of PMF1 methylation in association with bladder cancer progression.

Authors:  Ainel Aleman; Virginia Cebrian; Miguel Alvarez; Virginia Lopez; Esteban Orenes; Lidia Lopez-Serra; Ferran Algaba; Joaquin Bellmunt; Antonio López-Beltrán; Pilar Gonzalez-Peramato; Carlos Cordon-Cardo; Javier García; Javier García del Muro; Manel Esteller; Marta Sánchez-Carbayo
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

Review 5.  CpG island methylator phenotype (CIMP) in cancer: causes and implications.

Authors:  Jens M Teodoridis; Catriona Hardie; Robert Brown
Journal:  Cancer Lett       Date:  2008-05-08       Impact factor: 8.679

6.  CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma.

Authors:  Ichiro Kagara; Hideki Enokida; Kazumori Kawakami; Ryouichirou Matsuda; Kazuki Toki; Hiroaki Nishimura; Takeshi Chiyomaru; Shuichi Tatarano; Toshihiko Itesako; Ken Kawamoto; Kenryu Nishiyama; Naohiko Seki; Masayuki Nakagawa
Journal:  J Urol       Date:  2008-05-21       Impact factor: 7.450

7.  Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.

Authors:  Henk M W Verheul; Brenda Salumbides; Karen Van Erp; Hans Hammers; David Z Qian; Tolib Sanni; Peter Atadja; Roberto Pili
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

8.  Identification of novel epigenetic markers for clear cell renal cell carcinoma.

Authors:  Gul S Dalgin; Michele Drever; Tara Williams; Thomas King; Charles DeLisi; Louis S Liou
Journal:  J Urol       Date:  2008-07-18       Impact factor: 7.450

9.  Germline SDHB mutations and familial renal cell carcinoma.

Authors:  Christopher Ricketts; Emma R Woodward; Pip Killick; Mark R Morris; Dewi Astuti; Farida Latif; Eamonn R Maher
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506

10.  Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors.

Authors:  A H S Gylling; T T Nieminen; W M Abdel-Rahman; K Nuorva; M Juhola; E I Joensuu; H J Järvinen; J-P Mecklin; M Aarnio; P T Peltomäki
Journal:  Carcinogenesis       Date:  2008-06-12       Impact factor: 4.944

View more
  27 in total

Review 1.  MicroRNAs in biliary diseases.

Authors:  Patricia Munoz-Garrido; Maite García-Fernández de Barrena; Elizabeth Hijona; Miguel Carracedo; José J G Marín; Luis Bujanda; Jesús M Banales
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

Review 2.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

Review 3.  Oncological Ligand-Target Binding Systems and Developmental Approaches for Cancer Theranostics.

Authors:  Jaison Jeevanandam; Godfred Sabbih; Kei X Tan; Michael K Danquah
Journal:  Mol Biotechnol       Date:  2021-01-09       Impact factor: 2.695

4.  Pesticide use and LINE-1 methylation among male private pesticide applicators in the Agricultural Health Study.

Authors:  Melannie Alexander; Stella Koutros; Matthew R Bonner; Kathryn Hughes Barry; Michael C R Alavanja; Gabriella Andreotti; Hyang-Min Byun; Ligong Chen; Laura E Beane Freeman; Jonathan N Hofmann; Freya Kamel; Lee E Moore; Andrea Baccarelli; Jennifer Rusiecki
Journal:  Environ Epigenet       Date:  2017-05-03

Review 5.  Tumour and patient factors in renal cell carcinoma-towards personalized therapy.

Authors:  Ahmed Q Haddad; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2015-04-14       Impact factor: 14.432

Review 6.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

7.  Reduced expression of Slit2 in renal cell carcinoma.

Authors:  Wei-Jie Ma; Yu Zhou; Dan Lu; Dong Dong; Xiao-Jun Tian; Jie-Xi Wen; Jun Zhang
Journal:  Med Oncol       Date:  2013-11-15       Impact factor: 3.064

Review 8.  DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.

Authors:  Javier C Angulo; Jose I López; Santiago Ropero
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

9.  Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.

Authors:  Hyunseok Kang; Theresa W Gillespie; Michael Goodman; Seth A Brodie; Mina Brandes; Maria Ribeiro; Suresh S Ramalingam; Dong M Shin; Fadlo R Khuri; Johann Christoph Brandes
Journal:  Cancer       Date:  2014-03-24       Impact factor: 6.860

10.  Elevated microRNA-185 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in clear cell renal cell carcinoma.

Authors:  Hai-Xia Yuan; Jian-Ping Zhang; Wen-Tao Kong; Yu-Jun Liu; Zong-Ming Lin; Wen-Ping Wang; Jian-Ming Guo
Journal:  Tumour Biol       Date:  2014-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.